NASDAQ:CYCNCyclerion Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cyclerion Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.89 +0.53 (+12.16 %) (As of 08/11/2020 09:41 AM ET) Add Compare Share Today's Range$4.20Now: $4.89▼$5.0950-Day Range$3.46MA: $4.98▼$7.1452-Week Range$1.69Now: $4.89▼$14.83Volume455,240 shsAverage Volume304,405 shsMarket Capitalization$165.87 millionP/E RatioN/ADividend YieldN/ABeta1.01 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media There is no company description available for Cyclerion Therapeutics Inc.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Cyclerion Therapeutics. Previous Next 2.5 Community Rank Outperform VotesCyclerion Therapeutics has received 25 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCyclerion Therapeutics has received 26 “underperform” votes. (Add your “underperform” vote.)Community SentimentCyclerion Therapeutics has received 50.98% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cyclerion Therapeutics and other stocks. Vote “Outperform” if you believe CYCN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CYCN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCyclerion Therapeutics does not currently pay a dividend.Dividend GrowthCyclerion Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cyclerion Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 10.70% of the stock of Cyclerion Therapeutics is held by insiders.Percentage Held by Institutions66.78% of the stock of Cyclerion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Cyclerion Therapeutics is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cyclerion Therapeutics is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCyclerion Therapeutics has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.70 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CYCN Previous Symbol CUSIPN/A CIKN/A Webwww.cyclerion.com Phone857-327-8778Debt Debt-to-Equity Ratio0.70 Current Ratio3.81 Quick Ratio3.81Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$4.51 million Price / Sales36.78 Cash FlowN/A Price / Cash FlowN/A Book Value$3.56 per share Price / Book1.37Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-123,010,000.00 Net Margins-2,006.33% Return on Equity-102.19% Return on Assets-56.08%Miscellaneous EmployeesN/A Outstanding Shares33,920,000Market Cap$165.87 million Next Earnings Date11/10/2020 (Estimated) OptionableNot Optionable $4.89 +0.53 (+12.16 %) (As of 08/11/2020 09:41 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CYCN News and Ratings via Email Sign-up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter. Cyclerion Therapeutics (NASDAQ:CYCN) Frequently Asked Questions How has Cyclerion Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Cyclerion Therapeutics' stock was trading at $2.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CYCN stock has increased by 68.6% and is now trading at $4.89. View which stocks have been most impacted by Coronavirus. When is Cyclerion Therapeutics' next earnings date? Cyclerion Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Cyclerion Therapeutics. How were Cyclerion Therapeutics' earnings last quarter? Cyclerion Therapeutics Inc (NASDAQ:CYCN) released its quarterly earnings results on Monday, August, 3rd. The company reported ($0.70) earnings per share for the quarter. The business had revenue of $0.75 million for the quarter. Cyclerion Therapeutics had a negative net margin of 2,006.33% and a negative return on equity of 102.19%. View Cyclerion Therapeutics' earnings history. Has Cyclerion Therapeutics been receiving favorable news coverage? News articles about CYCN stock have trended positive this week, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cyclerion Therapeutics earned a news sentiment score of 2.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news about Cyclerion Therapeutics. Are investors shorting Cyclerion Therapeutics? Cyclerion Therapeutics saw a decrease in short interest in the month of July. As of July 31st, there was short interest totaling 904,600 shares, a decrease of 13.0% from the July 15th total of 1,040,000 shares. Based on an average daily volume of 242,300 shares, the days-to-cover ratio is presently 3.7 days. Currently, 3.9% of the company's shares are short sold. View Cyclerion Therapeutics' Short Interest. Who are some of Cyclerion Therapeutics' key competitors? Some companies that are related to Cyclerion Therapeutics include RAPT Therapeutics (RAPT), Corbus Pharmaceuticals (CRBP), Cue Biopharma (CUE), Syros Pharmaceuticals (SYRS), Radius Health (RDUS), Viking Therapeutics (VKTX), Legend Biotech (CALT), Crinetics Pharmaceuticals (CRNX), Molecular Templates (MTEM), Ardelyx (ARDX), Prothena (PRTA), Kala Pharmaceuticals (KALA), AnaptysBio (ANAB), Protagonist Therapeutics (PTGX) and Tocagen (TOCA). View all competitors. What other stocks do shareholders of Cyclerion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclerion Therapeutics investors own include Fulcrum Therapeutics (FULC), Ovid Therapeutics (OVID), VBI Vaccines (VBIV), vTv Therapeutics (VTVT), Abeona Therapeutics (ABEO), Capricor Therapeutics (CAPR), Galmed Pharmaceuticals (GLMD), Lexicon Pharmaceuticals (LXRX), Onconova Therapeutics (ONTX) and Opko Health (OPK). What is Cyclerion Therapeutics' stock symbol? Cyclerion Therapeutics trades on the NASDAQ under the ticker symbol "CYCN." Who are Cyclerion Therapeutics' major shareholders? Cyclerion Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include New York State Common Retirement Fund (0.42%), Russell Investments Group Ltd. (0.10%), State Board of Administration of Florida Retirement System (0.03%) and UBS Group AG (0.02%). Company insiders that own Cyclerion Therapeutics stock include Amy W Schulman, Andreas Busch, Mark G Currie and William Huyett. View institutional ownership trends for Cyclerion Therapeutics. Which institutional investors are selling Cyclerion Therapeutics stock? CYCN stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. Company insiders that have sold Cyclerion Therapeutics company stock in the last year include Mark G Currie, and William Huyett. View insider buying and selling activity for Cyclerion Therapeutics. Which institutional investors are buying Cyclerion Therapeutics stock? CYCN stock was purchased by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, State Board of Administration of Florida Retirement System, and Russell Investments Group Ltd.. Company insiders that have bought Cyclerion Therapeutics stock in the last two years include Amy W Schulman, Andreas Busch, and Mark G Currie. View insider buying and selling activity for Cyclerion Therapeutics. How do I buy shares of Cyclerion Therapeutics? Shares of CYCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cyclerion Therapeutics' stock price today? One share of CYCN stock can currently be purchased for approximately $4.89. How big of a company is Cyclerion Therapeutics? Cyclerion Therapeutics has a market capitalization of $165.87 million and generates $4.51 million in revenue each year. What is Cyclerion Therapeutics' official website? The official website for Cyclerion Therapeutics is www.cyclerion.com. How can I contact Cyclerion Therapeutics? Cyclerion Therapeutics' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at 857-327-8778 or via email at [email protected] This page was last updated on 8/11/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
